Fig. 3: Next-generation anti-CD3 × anti-CD28 × anti-CD38 tri-specific T-cell-engaging antibody.
From: Overcoming the challenges associated with CD3+ T-cell redirection in cancer
The diagram depicts a tri-specific antibody targeting anti-CD3ε and anti-CD28 on T cells as well as anti-CD38 on multiple myeloma cells. Co-engagement of CD3, CD28 and CD38 results in efficient T-cell stimulation and activation, cytokine release, and redirection of T-cell-mediated cytotoxicity to myeloma cells.
